Press release
Parkinson's Disease Psychosis Market Size (7MM) was ~USD 665 million in 2023 and It is expected to grow at a significant CAGR by 2034, estimates DelveInsight | Enterin Inc., Otsuka Pharmaceutical Development & Commercialization Inc., ACADIA Pharmaceutical
Parkinson's Disease Psychosis Drugs Market
Explore the intricate details of the Parkinson's Disease Psychosis Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Parkinson's Disease Psychosis Market Forecast @ https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Parkinson's Disease Psychosis Market Report
• In October 2025, Johns Hopkins University conducted a clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks. Participants will receive both AGB101 and a placebo to take once a day for 6 weeks, with a 4-week washout in between. Participation will also involve physical/neurological exams, questionnaires, paper and pencil tests, providing blood and urine samples, and completing two MRI exams.
• The total diagnosed prevalent cases of Parkinson's disease in the 7MM were 2,718 thousand in 2023 and are expected to increase at a significant CAGR of throughout the forecast period.
• In 2023, Japan contributed 258 thousand diagnosed prevalent cases of Parkinson's disease, representing almost 9% of the total diagnosed prevalence across the 7MM.
• Among the 7MM, EU4 and the UK accounted for nearly 353 thousand diagnosed prevalent cases of PDP, and these cases are expected to increase during the forecast period (2024-2034).
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of PDP, with 134 thousand cases, followed by France and Italy in 2023. On the other hand, the UK had the lowest diagnosed prevalent population in EU4 and the UK in 2023.
• In Japan, there were around 74 thousand diagnosed prevalent cases of PDP in 2023. These cases are expected to increase at a significant CAGR.
• The leading Parkinson's Disease Psychosis Companies such as Enterin Inc., Otsuka Pharmaceutical Development & Commercialization Inc., ACADIA Pharmaceuticals Inc., Tasly Pharmaceutical Group Co., Ltd, and others.
• Promising Parkinson's Disease Psychosis Therapies such as aripiprazole, Pimavanserin tartrate (ACP-103), pimavanserin tartrate, ACP-103 and others.
Navigate the complexities of the Parkinson's Disease Psychosis Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Parkinson's Disease Psychosis Market Forecast. Click here to get more insights @ https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Parkinson's Disease Psychosis Epidemiology Segmentation in the 7MM
• Total Parkinson's Disease Psychosis Diagnosed Prevalent Cases
• Total Parkinson's Disease Psychosis Treated Cases
Delve deep into the Parkinson's Disease Psychosis Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Parkinson's Disease Psychosis Market Forecast. Click here to shape the future @ https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Parkinson's Disease Psychosis Emerging Drugs
• ENT-012: Enterin Inc.
ENT-012 is undergoing Phase IIa clinical trials to evaluate its efficacy and safety in treating psychosis associated with Parkinson's disease. This phase focuses on assessing the drug's ability to reduce the severity of psychotic symptoms, measured through the Scale for the Assessment of Positive Symptoms (SAPS). Preliminary results suggest that ENT-012 is generally well-tolerated, with side effects similar to those of other SSRIs, such as gastrointestinal disturbances, headaches, and fatigue. The trial is designed to gather more comprehensive data on its impact on patients, and results are expected in the near future.
Unlock insights into the Parkinson's Disease Psychosis Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Parkinson's Disease Psychosis Market Forecast. Click here @ https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Parkinson's Disease Psychosis Treatment Landscape
Symptomatic treatment is critical in managing Parkinson's disease Psychosis, which often requires a careful balance between addressing psychotic symptoms and minimizing the exacerbation of motor issues commonly associated with Parkinson's disease. Antipsychotic medications are frequently prescribed, but many traditional options can worsen motor symptoms, making the choice of treatment particularly challenging. As a result, newer medications like ENT-012, a selective serotonin reuptake inhibitor, are being explored to provide effective symptom relief without negatively impacting motor function. Overall, the treatment landscape for Parkinson's disease Psychosis is marked by a combination of symptomatic management, ongoing research, and supportive care. While there is currently no definitive cure, advancements in Parkinson's disease Psychosis clinical trials and emerging therapies offer hope for more effective and targeted treatment strategies in the future. Collaborative efforts among healthcare professionals, researchers, and patient organizations are crucial in improving outcomes for individuals affected by this challenging condition. The total market size of the PDP treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments.
Parkinson's Disease Psychosis Market Outlook
Parkinson's disease Psychosis (PDP) is a complex condition characterized by the emergence of psychotic symptoms, such as hallucinations and delusions, in patients with Parkinson's disease. The treatment landscape for PDP is still evolving, as the interplay between neurodegeneration and psychosis complicates the establishment of standardized treatment protocols. Currently, there are no universally approved therapies specifically for PDP, and management primarily focuses on alleviating symptoms while ensuring the patient's overall well-being. Ongoing research into the underlying mechanisms of Parkinson's disease Psychosis is paving the way for innovative treatment options. Investigational therapies, including ENT-012, are being evaluated in clinical trials to determine their effectiveness and safety. These efforts aim to identify new pharmacological approaches that specifically target the serotonergic system to mitigate psychotic symptoms more effectively.
Gain a strategic edge in the Parkinson's Disease Psychosis Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Parkinson's Disease Psychosis Market Forecast. Click here to lead in advancements @ https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Parkinson's Disease Psychosis Companies
Enterin Inc., Otsuka Pharmaceutical Development & Commercialization Inc., ACADIA Pharmaceuticals Inc., Tasly Pharmaceutical Group Co., Ltd, and others.
Scope of the Parkinson's Disease Psychosis Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Parkinson's Disease Psychosis Companies- Enterin Inc., Otsuka Pharmaceutical Development & Commercialization Inc., ACADIA Pharmaceuticals Inc., Tasly Pharmaceutical Group Co., Ltd, and others.
• Parkinson's Disease Psychosis Therapies- aripiprazole, Pimavanserin tartrate (ACP-103), pimavanserin tartrate, ACP-103 and others.
• Parkinson's Disease Psychosis Therapeutic Assessment: Parkinson's Disease Psychosis current marketed and Parkinson's Disease Psychosis emerging therapies
• Parkinson's Disease Psychosis Market Dynamics: Parkinson's Disease Psychosis market drivers and Parkinson's Disease Psychosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Parkinson's Disease Psychosis Unmet Needs, KOL's views, Analyst's views, Parkinson's Disease Psychosis Market Access and Reimbursement
Discover more about therapies set to grab major Parkinson's Disease Psychosis market share @ Parkinson's Disease Psychosis Treatment Landscape- https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Contents
1. Key Insights
2. Report Introduction
3. Parkinson's Disease Psychosis (PDP) Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Emerging Therapies
10.1. Key Cross Competition of Emerging Drugs
11. Marketed Therapies
12. Parkinson's Disease Psychosis: Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18: DelveInsight Capabilities
19: Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Psychosis Market Size (7MM) was ~USD 665 million in 2023 and It is expected to grow at a significant CAGR by 2034, estimates DelveInsight | Enterin Inc., Otsuka Pharmaceutical Development & Commercialization Inc., ACADIA Pharmaceutical here
News-ID: 4279197 • Views: …
More Releases from DelveInsight Business Research LLP
MAC Lung Disease Market Size (7MM) was ~USD 474 million in 2023 and is projected …
DelveInsight's "MAC Lung Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of MAC lung disease, historical and forecasted epidemiology, as well as the MAC lung disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the MAC Lung Disease Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive…
Prader-Willi Syndrome Treatment Market Size in the 7MM was more than ~USD 600 mi …
DelveInsight's "Prader-Willi Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Prader-Willi Syndrome, historical and forecasted epidemiology as well as the Prader-Willi Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The Prader-Willi Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prader-Willi Syndrome…
Graft Versus Host Disease Market Size (7MM) is expected to grow from USD 1,626 m …
DelveInsight's "Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology and the Graft Versus Host Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the Graft Versus Host Disease Market: Uncover drug uptake, treatment dynamics, and epidemiological trends…
Short Bowel Syndrome Market in the 7MM is expected to grow from USD 2,450 millio …
DelveInsight's "Short Bowel Syndrome Treatment Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Short Bowel Syndrome, historical and forecasted epidemiology as well as Short Bowel Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the Short Bowel Syndrome Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
